Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology

NCT04798989 is registered in ClinicalTrials.gov with Tisento Therapeutics as lead sponsor.

NCT NCT04798989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04798989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology
Lead sponsor
Tisento Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 2, 2021
Completion date
November 28, 2022
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease with vascular pathology